Plasmodium vivax: comparison of immunogenicity among proteins expressed in the cell-free systems of Escherichia coli and wheat germ by suspension array assays by Rui, Edmilson et al.
METHODOLOGY Open Access
Plasmodium vivax: comparison of immunogenicity
among proteins expressed in the cell-free
systems of Escherichia coli and wheat germ by
suspension array assays
Edmilson Rui
1, Carmen Fernandez-Becerra
1, Satoru Takeo
2, Sergi Sanz
1, Marcus VG Lacerda
3, Takafumi Tsuboi
2,4
and Hernando A del Portillo
1,5*
Abstract
Background: In vitro cell-free systems for protein expression with extracts from prokaryotic (Escherichia coli)o r
eukaryotic (wheat germ) cells coupled to solid matrices have offered a valid approach for antigen discovery in
malaria research. However, no comparative analysis of both systems is presently available nor the usage of
suspension array technologies, which offer nearly solution phase kinetics.
Methods: Five Plasmodium vivax antigens representing leading vaccine candidates were expressed in the E. coli
and wheat germ cell-free systems at a 50 μl scale. Products were affinity purified in a single-step and coupled to
luminex beads to measure antibody reactivity of human immune sera.
Results: Both systems readily produced detectable proteins; proteins produced in wheat germ, however, were
mostly soluble and intact as opposed to proteins produced in E. coli, which remained mostly insoluble and highly
degraded. Noticeably, wheat germ proteins were recognized in significantly higher numbers by sera of P. vivax
patients than identical proteins produced in E. coli.
Conclusions: The wheat germ cell-free system offers the possibility of expressing soluble P. vivax proteins in a
small-scale for antigen discovery and immuno-epidemiological studies using suspension array technology.
Background
The recent call for malaria eradication has re-empha-
sized the importance of bringing Plasmodium vivax into
the research agenda [1]. Plasmodium vivax remains the
most widely distributed human malaria parasite with
2.85 billion people living at risk of infection [2]. Notice-
ably, the number of yearly clinical cases seems to be
increasing from 70-80 million [3] to 300 million cases
[4] and these include cases of severe disease and death
exclusively associated with P. vivax [5,6]. Moreover,
experts agree that present tools against Plasmodium fal-
ciparum will not be effective against P. vivax,r e i n f o r -
cing the development of control measurements for this
species [7]. Among these tools, vaccines continue to
represent the most cost-effective control measurement
but unfortunately vaccine development in P. vivax lags
well behind that of P. falciparum [8].
The genomes of human malaria parasites encode
approximately 5,400 coding genes opening an avenue
for antigen discovery in this species [9]. Unfortunately,
cell-based expression systems have met limited success
to obtain soluble proteins largely attributed to the high
AT-content, the existence of long stretches of repeated
amino acid sequences and much larger proteins than
their homologues in other eukaryotes [10]. In contrast
to cell-based systems, cell-free expression systems for
protein synthesis with extracts from prokaryotic or
eukaryotic cells has offered a valid alternative to express
soluble proteins [11]. In the case of malaria, using the
Escherichia coli cell-free system, Doolan and co-workers
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proteins subsequently coupled to solid arrays and ana-
lysed with immune sera discovering putative new anti-
gens [12]. Using this same approach, expression of 1,204
P. falciparum proteins later expanded these analysis and
predicted new antigens [13]. Parallel efforts were
reported on the use of cell-free extracts from wheat
germ to similarly produce hundreds of P. falciparum
proteins [14,15]. More recently, the wheat germ expres-
sion system has been used for antigen discovery in P.
vivax [16]. Thus, 89 different soluble proteins were
expressed and shown to be immunogenic on analyses of
protein arrays and immune sera. Together, this data
demonstrates that cell-free expression systems coupled
to protein arrays offer a scalable platform for antigen
discovery in malaria.
Suspension array technologies with high-throughput
capacity to simultaneously analyse several proteins with
minimal amount of immune sera have also been devel-
o p e da n du s e di na n a l y s i so fm u l t i p l em a l a r i av a c c i n e
candidates as well as in developing functional assays
[17-20]. Suspension arrays offer several advantages as
compared to flat protein arrays including nearly solution
phase kinetics and total assay sensitivity [21]. The aim
of this study was to develop a small-scale method for
soluble expression of P. vivax proteins using the E. coli
and wheat germ cell-free systems and to compare their
usage by multiplexing assays.
Methods
Human samples
Human plasma samples were obtained from endemic
areas of Brazil and from a non-endemic region. The first
group comprised immune sera from adults living in the
Brazilian Amazon [22]. The other group comprised sera
from four healthy adult volunteers living in the city of
Barcelona (Spain) that have never been exposed to
malaria or visited malaria endemic regions. These stu-
dies received the ethical approval of Local Institutional
Reviewing Boards.
Construction of plasmids
Plasmid pIVEX1.4d for expression in wheat germ and
pIVEX2.4d for expression in E. coli were purchased from
Roche and modified by inserting GST after the 6xHis tag
sequence. Modified plasmids were termed pIVEXGST1.4d
and pIVEXGST2.4d (Figure 1). Both vectors carry the
same T7-DNA promoter elements, the ampicillin select-
able marker and identical His-GST tags in the same posi-
tions. The following proteins were engineered into these
vectors: PvMSP1-19 (1590-1699 aa, id PVX_099980) and
PvMSP1-Nter (170-675 aa, id PVX_099980); PvDBP-RII
(196-521 aa, id PVX_110810); PvCSP-S (51-319 aa, id
PVX_119355); PvMSP5 (full length, id PVX_003770);
PvMSP7 (full length, id PVX_082695 (Figure 2). Further
information on these proteins and primers used for ampli-
fications can be obtained as supplementary information
(Additional file 1).
The circumsporozoite antigen of P. vivax is dimorphic
based on the central repeat region and the two alleles,
VK210- and VK247-type, share no immunological cross-
reactivity [23]. Therefore, a recombinant chimeric
PvCSP protein containing VK210-(PVX_119355) and
VK247-type (GenBank#M69059, P. vivax PNG strain)
amino acid repeat sequences (PvCSP-c) which may
cover the vivax parasite population globally was devel-
oped (Figure 3). The PvCSP-c was constructed and
expressed in a large-scale wheat germ cell-free system
Figure 1 Construction of recombinant expression vectors.
Expression vectors for wheat germ (pIVEX1.4) and E. coli (pIVEX2.4)
were originally purchased from Roche. GST was subsequently
introduced into these vectors between the 6xHis tag and the
multiple cloning site (MCS) to generate plasmids pIVEGST1.4 and
pIVEXGST2.4. Amino acids between GST and P. vivax proteins are
the same for all constructs.
Figure 2 Schematic representation of recombinant proteins
expressed in E. coli and wheat germ. Merozoite surface protein 1
N-terminus (MSP1-Nter), Merozoite surface protein 1 C-terminus
(MSP1-19), Duffy binding protein - region II (PvRDBP-RII), Merozoite
surface protein 5 (PvMSP5), Circumsporozoite protein - Salvador
strain (PvCSP-S), Merozoite surface protein 7 (PvMSP7), 6His-tagged
Gluthatione-S-transferase (6His-GST), Circumsporozoite protein -
chimeric (PvCSP-c). Numbers indicate amino acid (aa) residues.
Predicted sizes of recombinant proteins in aa are shown to the
right.
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nucleotide sequences of PvCSP (SalI strain, VK210 type:
PVX_119355) excluding the signal peptide and the GPI
anchor signal, with addition of penta-His-tag sequence
at the C-terminus, was amplified from SalI gDNA by
PCR using VK210-F and VK210-R primers, and was
cloned at the EcoRV site into the pEU-E01-MCS plas-
mid (CellFree Sciences) in the presence of both EcoRV
restriction enzyme and T4 DNA ligase generating the
pEU-PvCSP210 construct without original EcoRV site.
The pEU-PvCSP210 was then inversely amplified by
PCR using antisense-primer encoding the four times of
the VK210-repeat amino acid sequence “GQPAGDRAD”
at the 5’ end with EcoRV site (PvCSP-c-R) (Additional
file 1) and sense-primer encoding the three times of the
VK247-repeat amino acid sequence “GANGAGNQP” at
the 5’ end with EcoRV site (PvCSP-c-F) (Additional file
1). Then the PCR product was digested with EcoRV,
and self ligated after the gel-purification of the restricted
DNA fragment. Finally, the presence of tetra-VK210-
type sequence was confirmed followed by tri-VK247-
type repeat amino acid sequences after the nucleotide
sequencing of the final pEU-PvCSP-c plasmid (Figure 3).
Deduced amino acid sequences, Gly2 to Asp106 and
Asn134 to Cys199 in PvCSP-c was identical to Gly23 to
Asp127 and Asn286 to Cys347 based on the SalI sequence,
PVX_ 119355, and Gly108 to Pro134 in PvCSP-c was
identical to Gly248 to Pro274 based on the deduced
amino acid sequence from P. vivax PNG strain, M69059.
In vitro protein synthesis
In vitro protein synthesis followed the original manufac-
turers’ instructions (Roche) and was done on a 50 μl
scale, excepting for PvCSP-c (see below). Expressed pro-
teins were purified on GST SpinTrap purification col-
umns (GE Healthcare). Briefly, soluble fractions from
cell-free system extracts were applied to a Glutathione
Sepharose
® 4B column that had been equilibrated with
PBS. The column was washed with PBS and the bound
GST-HBx fusion protein was eluted with 10 mM glu-
tathione in 50 mM Tris-HCl, pH 8.0. Eluted proteins
were extensively dialyzed in PBS to remove glutathione.
Proteins were analysed by SDS-page and Western blot
and quantified as described else where [24]
Larger scale wheat germ cell-free protein synthesis
The recombinant PvCSP-c protein was synthesized with
the wheat germ cell-free protein expression system
using the bilayer translation reaction method on a 30 ml
scale as manufacturer’s recommendation (CellFree
Sciences) [14]. The PvCSP-c protein was affinity purified
by Ni-affinity chromatography as described previously
[25]. Briefly, add imidazole (pH 8.0) in the translation
reaction mixture (final concentration, 20 mM) and then
add Ni-NTA beads (QIAGEN, Valencia, CA). Incubate
the tube for 16 h on a continuous rotator, at 4°C, for
the binding of proteins on to the beads. Transfer the
solution with the beads into a Poly-Prep chromatogra-
phy column (Bio-Rad, Hercules, CA). Wash the beads
by five bed-volumes of PBS containing 30 mM imida-
zole three times and then elute the recombinant protein
with one bed-volume of PBS containing 500 mM
imidazole.
Covalent coupling of recombinant proteins to beads
BioPlex carboxylated beads (Bio-Rad) were covalently
coated with the different recombinant proteins following
the manufacturer’si n s t r u c t i o n s( B i o P l e xA m i n eC o u -
pling Kit). Briefly, activated beads (1.25 × 10
6 beads)
were resuspended in 100 μlo fP B Sa n d1μg of each
recombinant protein used per coupling reaction. Incuba-
tion under rotation was done at 4°C overnight and
coupled beads were washed with 500 μl of PBS pH 7.4.
After re-suspending coupling beads in 250 μlo fb l o c k -
ing buffer and further incubation under rotation at
room temperature for 30 min, beads were washed with
500 μl of storage buffer and centrifuged for six minutes
at 14,000 × g. Pellets were resuspended into 125 μlo f
the same buffer and stored at 4°C protected from light
until use.
Analysis of coupled beads on the BioPlex system
Coupled beads were analysed in the Bioplex system as
previously described [20] with slight modifications.
Briefly, circa 3,000 coated beads were used for each
assay. Frozen plasma samples were thawed at room tem-
perature, diluted 1:50 in assay buffer and 50 μla l i q u o t s
Figure 3 Schematic representation of the cloning strategy to
produce a chimeric circumsporozoite protein contaning
canonical major repeats. Recombinant chimeric PvCSP protein
containing VK210-(PVX_119355) and VK247-type (GenBank#M69059,
P. vivax PNG strain) amino acid repeat sequences (PvCSP-c).
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quots of 50 μl of Biotinylated human IgG antibody
(Sigma) diluted 1:10,000 and of phycoerythrin conju-
gated streptavidin diluted to 1 μg/ml were used in sub-
sequent incubations. Beads were re-suspended in 125 μl
of assay buffer (BioRad) and analysed on the BioPlex100
system and results were expressed as median fluorescent
intensity (MFI).
Statistical analysis
T-test and chi-square or fisher exact test were used to
compare mean levels for prevalence, respectively,
between groups. Averages were expressed as geometric
mean (GM) plus 95% confidence intervals (CI). To eval-
uate the statistical measure of agreement between two
independent proteins the index Kappa was calculated.
Results
Cloning and expression of Plasmodium vivax proteins
Expression of genes encoding five P. vivax proteins:
PvMsp1-19, PvMsp1-Nter, PvMsp5, PvMsp7, PvDBP-
RII, PvCsp-S and GST as control was initially attempted
in E. coli and wheat germ cell-free expression systems
using commercially available vectors (Roche). Yields,
however, were very low and highly degraded as detected
by Western blot analysis. It was thus decided to incor-
porate a GST tag into these vectors (Figure 1) as GST
increased the solubility and yields of different recombi-
nant proteins [26]. Noticeably, when cloned into these
vectors, both expression systems produced readily
detectable proteins by Western blot analysis under redu-
cing condition (Figure 4). Proteins expressed by the cell-
free E. coli system, however, were mostly degraded and
showed low amounts of intact proteins with predicted
sizes (Figure 4A). In contrast, soluble proteins expressed
in wheat germ cell-free system were of predicted sizes
and had much less degradation products (Figure 4B). All
proteins produced by wheat germ system were affinity-
purified to 60-85% and yielded 1-10ug/50ul (Additional
file 2). Soluble purified proteins were coupled to indivi-
dual bioplex beads and coupling efficiency was verified
prior to multiplexing using an anti-GST or anti-his anti-
body (Additional file 3).
Proteins produced by wheat germ system are recognized
by significantly higher number of immune sera than
those produced by E. coli
Only three soluble proteins produced in the 50 μls c a l e
in E. coli could be purified in a single-step and coupled
to Bioplex beads using exactly the same methodology as
those produced and purified by wheat germ system. A
comparison of naturally acquired humoral IgG
responses against these proteins was thus made using
immune sera of 40 malaria patients from Brazil known
to have large reactivity against PvMSP1 [22]. GST
values were subtracted from MFI values obtained
against individual recombinant proteins and the cut-off
defined as the mean value of control sera +3 standard
deviations. Noticeably, proteins produced in the wheat
germ system were recognized in significantly higher
numbers than those produced in the E. coli system
(MSP1-19 wheat germ 37/40 (92.5%) vs MSP1-19 E. coli
19/40 (47.5%), p = 0.000; MSP1-N wheat germ 26/40
(65%) vs MSP1-N E. coli 8/40 (20%), p = 0.000; MSP5
w h e a tg e r m3 4 / 4 0( 8 5 % )v sM S P 5E. coli 23/40 (57.5%)
(p = 0.001) (Figure 5). Moreover, values of geometric
means of all proteins produced in wheat germ system
were significantly higher than those produced in E. coli
system and 95% confidence intervals reinforced such
differences. This data demonstrates that identical solu-
ble proteins expressed in wheat germ system and
coupled to bioplex beads are better recognized by the
same immune sera than those expressed by E. coli
system.
Multiplex assays with proteins produced in wheat germ
system as an alternative platform for antigen discovery
To illustrate the use of soluble proteins produced by
wheat germ system in a 50 μl scale and multiplexing
assays for immuno-epidemiological studies, the
responses of other proteins also considered important
targets for P. vivax vaccine development were deter-
mined. These include (besides MSP1-19, MSP1-N, and
MSP5), MSP7 [27], PvDBP-RII [28], and CSP [29].
Moreover, a chimeric CSP protein produced in large-
scale in wheat germ and containing the two major allele
repeats of PvCSP was also included (Figure 3 and Addi-
tional file 1). Of note, for this analysis a different group
of 40 sera pertaining to other individuals with no parti-
cular strong reactivity against PvMSP1 was used [22].
Figure 4 Expression of Plasmodium vivax proteins in cell-free
systems. A. Expression of proteins in the E. coli cell-free system. B.
Expression of proteins in the wheat germ cell-free system. Both
extracts were separated in soluble and insoluble protein fractions by
centrifugation (14,000 g/20 mim/4°C). Soluble fractions were
analysed by Western blot using anti-GST (HRP) antibody. Molecular
weights in kilo-Daltons are indicated to the left and soluble Pv-
fusion proteins of predicted sizes are marked with an arrow.
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serum diluted 1:100 and then simultaneously using the
same quantity and the same dilution. At this dilution,
the same sera reacting against PvCSP-S reacted against
PvCSP-c even though a subtraction effect was detected
in singleplex vs multiplex (Additional file 4). Thus, dilu-
tions of sera in these assays must be taken into consid-
eration to avoid missing immune responders to different
alleles of the same protein. The data corroborated the
immunogenicity of all these proteins albeit, as expected,
to different levels (MSP1-19 80%, MSP1-Nter 60%,
MSP5 70%, MSP7 22.5%, PvDBP-RII 50%, PvCSP-S 45%
and PvCSP-c 65%) (Figure 6). Moreover, a cross-com-
parison between responses to the different proteins
revealed, for instance, that sera that reacted against
PvMSP1-19 also reacted against PvMSP1-N (58.06%),
PvMSP5 (64.52%), PvMSP7 (9.68%), PvDBP-RII
(45.16%), PvCSP-S (45.16%) and PvCSC-c (74%) (Figure
7). Values for all other cross-comparisons showed simi-
lar results with varying percentages of recognition by
immune sera against any one particular protein and
comparisons with the others (Additional file 5). Of note,
t h e r ew e r eas i g n i f i c a n tl a rger percentage of immune
sera reacting against the chimeric CSP (PvCSP-c) as
opposed to the one expressing only one allele (PvCSP-
S). Moreover, cross-comparison of responses against
PvCSP-S and PvCSP-c demonstrated that 92.86% of sera
reacted against these two proteins.
Discussion
Protein arrays containing hundreds to thousands of
malarial proteins have been recently reported for anti-
gen discovery [13,15,16]. In these experiments, in vitro
transcribed/translated products are directly spotted into
solid matrices for analysis and reactivity against human
sera. The goal here was developing an alternative simple
small-scale method for soluble expression and single-
step affinity purification of proteins to be analysed by
suspension array technology. To this end, vectors
expressing GST fused to the protein of interest were
constructed to facilitate soluble expression of P. vivax
proteins in a 50 μl scale in the cell-free systems of E.
coli and wheat germ. Soluble proteins were affinity-puri-
fied in a single-step, coupled to luminex beads and ana-
lysed against immune sera from P. vivax patients.
Figure 5 Comparative analysis of immune responses to P.
vivax proteins expressed in the E. coli and wheat germ cell-
free systems by Bioplex. One μg of each affinity-purified protein
was individually coupled to beads and analysed by multiplex assays
using immune sera (1:100 dilution) pertaining to 40 different P. vivax
patients. Fluorescence was determined as the mean fluorescence
intensity (MFI). GST values were subtracted from MFI values
obtained against individual recombinant proteins and the cut-off
defined as the mean value of control sera + 3 standard deviations.
Circles represent samples which MFI values were below the cut-off
and were considered negative whereas squares represent samples
which MFI values were above the cut-off and were considered
positive. Geometric means and 95% confidence intervals are shown.
Figure 6 Naturally acquired humoral IgG immune responses to
proteins expressed in the wheat germ cell-free system. Human
IgG antibodies against P. vivax recombinant proteins were detected
by Bioplex. One μg of wheat germ cell-free-produced proteins were
individually coupled to beads and incubated with 40 different
individual plasma samples (1:100 dilution) followed by biotinylated
human IgG isotypes and detected using PE-streptavidin.
Fluorescence was determined as the mean fluorescence intensity
(MFI). GST values were subtracted from MFI values obtained against
individual recombinant proteins and the cut-off defined as the
mean value of control sera + 3 standard deviations. Only positive
values above the cut-off are represented as dots.
Figure 7 Cross comparisons of immune responses to PvMSP1-
19. Immune responses to different proteins in the same serum
using a 2 × 2 Table on the response distribution over proteins pairs.
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against proteins expressed in wheat germ system and
multiplexing of five leading vaccine candidates illu-
strated the use of this method for immuno-epidemiolo-
gical studies in P. vivax.
A major bottle-neck in antigen discovery for vaccine
development in malaria is the little success achieved in
producing soluble proteins in different cell-based or
viral systems. Thus, cell-based E. coli and baculo-virus
systems have reported expression of soluble malaria pro-
teins anywhere from 6.3-30% [10,30]. In these reports,
modifications involving codon optimization, construc-
tion of synthetic genes, extensive manipulations of cul-
ture conditions, different temperatures, and large
culture volumes were needed to achieve solubilisation of
proteins [10]. While these methods and expression sys-
tems remain highly valuable tools for structural and
functional studies, they are difficult to implement on
large-scale analysis of malarial proteins for antigen dis-
covery. Noticeably, the development of cell-free expres-
sion systems offered a valid and efficient alternative to
this objective. In fact, using malarial proteins expressed
in cell-free extracts of either E. coli or wheat germ and
analysed on flat solid arrays with immune sera, recent
reports have paved the way for genome-wide antigen
discovery of the two major human malaria parasites
[13,16]. In these systems, proteins are directly spotted
on linear flat surfaces with no formal demonstration of
solubility or purity of expressed products. As the goal of
these studies is the screening of thousand of antigens in
combination with powerful statistical analyses, the pre-
sence of false-positives have been considered negligible.
Increasing evidence, however, indicates that proteins
expressed in wheat germ cell-free system are more sui-
table for these analyses as they are mostly soluble and
retained enzymatic activity [15,31]. Moreover, suspen-
sion arrays offer major advantages when compared to
protein arrays including nearly solution phase kinetics
and total assay sensitivity [21].
The methodology reported here largely facilitates the
production of soluble proteins in a small-scale compati-
ble with automation and in quantities allowing analysis
of hundreds of sera (roughly 1 μg of soluble/affinity-pur-
ied protein can be used to screen approximately 250
sera) using suspension arrays. To illustrate this, we
expressed five leading vaccine candidates against two dif-
ferent life stages, the pre-erythrocytic stages (CSP) and
asexual blood stages (MSPs and DBP). CSP is considered
a leading vaccine candidate in P. falciparum [32] and the
homologous protein has entered clinical trials in P. vivax
[8]. PvCSP contains two major allele forms, PvCSP-
VK210 [29] and PvCSP-VK247 [23]. We expressed
PvCSP-VK210 in the 50 μl scale and also tested a chime-
rical protein composed of both major alleles (PvCSP-c)
produced in large-scale. Both proteins were readily
recognized by immune sera even though significantly lar-
ger number of sera reacted against the PvCSP-c protein
representing these two major alleles. The fact that lower
number of sera reacted against PvCSP-S could be due to
lower amounts of full CSP coupled to the beads as there
was a major degradation product detected by SDS-PAGE
(Additional file 2). Alternatively, these results are due to
the presence of both major alleles in this chimerical pro-
tein as both readily circulate in the Brazilian Amazon
[33]. In the absence of further evidence, this remains to
be investigated.
Proteins expressed during the asexual blood stages are
responsible for pathology associated with malaria and
are, therefore, the target of intense efforts to discover
antigens for vaccination. Naturally acquired humoral
immune responses against merozoite surface proteins
were thus initially analysed as they are involved in inva-
sion to red blood cells and are considered candidates to
develop sub-unit vaccines against malaria [27]. In parti-
cular, MSP1, MSP5 and MSP7 were studied as different
reports from these proteins indicate their potential in
vaccine development [8]. MSP1 and MSP5 are encoded
by single gene whereas MSP7 pertains to a highly var-
iant multi-allelic family [9]. As expected, results demon-
strated that MSP proteins are immunogenic in natural
infections. Moreover, results confirmed that MSP1-19 is
more immunogenic than MSP1-N [20] and that in spite
of MSP5 being highly polymorphic [34], it is also highly
immunogenic. Furthermore, in line with being a multi-
gene family differentially expressed during blood stages
[35], reactivity against MSP7 was lower than MSP1 or
MSP5. In addition to MSPs, the response against the
Duffy binding protein region II (PvDBP-II) a leading
vaccine candidate against P. vivax, was also analysed.
PvDBP-II is cysteine-rich and requires a complex series
of steps to fold it correctly [28]. Results confirmed the
immunogenicity of PvDBP-II in natural infections as
previously reported using sera from adult patients in
Brazil [33]. Whether these antibody responses against
different asexual blood stages are inhibitory as shown
for the PvDBP-II [36] awaits the development of func-
tional assays.
In summary, expression of soluble proteins from P.
vivax for analysis in multiplexing assays using the wheat
germ cell-free system in a 50 μl scale has been achieved.
In addition to the five leading vaccine candidates illus-
trating here this methodology, several other proteins
including subtelomeric variant Vir and PfamD proteins,
Pvs48/45, and several hypothetical antigenic proteins,
h a v eb e e ns o l u b l ye x p r e s s e da tt h i ss c a l e .U pt o1 0 0
proteins can be presently coupled to different beads and
analysed simultaneously with as little as one microliter
of immune sera. Prospective longitudinal studies from
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and clinical immunity using this methodology will com-
plement studies using protein arrays and will accelerate
antigen discovery and vaccine development in P. vivax.
Additional material
Additional file 1: Proteins and primers used in this study. ID,
identification. AA, amino acids. MW, molecular weight. IP, isoelectric
point. Columns to the right represente GST-fusion proteins. Sequence of
primers.
Additional file 2: Purification of proteins from wheat germ lysates.
Soluble fractions from wheat germ extracts were applied to a
Glutathione Sepharose
®® 4B column equilibrated with PBS. Columns
were washed with PBS and bound GST-fusion proteins eluted with 10
mM glutathione in 50 mM Tris-HCl, pH 8.0. Collected fractions were
analysed by SDS-PAGE. Molecular weights of standard control proteins
are indicated and soluble GST-fusion proteins are marked with an arrow.
Additional file 3: Coupling efficiency of proteins to activated beads.
Specific detection of 8 tagged Pv-protein on beads. Protein were
expressed in wheat germ cell free system, purified and 1 ug bound to
the beads. Prior to multiplexing, protein coupling was verified by
incubating coupled beads with mouse anti-Gst or anti-his (for PvCSP-c)
antibody followed by biotinylated anti-mouse IgG. The biotinylated
antibodies were detected using PE-streptavidin with the Luminex
analyzer beads, and fluorescence was determined in the mean
fluorescence intensity (MFI).
Additional file 4: Comparative analysis of immune responses to
PvCSP-S and PvCSP-c by singleplex and multiplex. Immune sera were
analysed in a single-vs multiplex assay. Values above 1 indicates
increased response as multiplex assay. Values below 1 indicates that
there was a decrease of the response as multiplex assay.
Additional file 5: Comparative analysis between responses to
different proteins in the same serum using 2 × 2 tables.
List of abbreviations
GST: Glutathione S-Transferase; MFI: Median fluorescent intensity; PE:
phycoerythrin
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